Catherine L Shuler

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1

Philip J. Mease, Désirée van der Heijde, Masato Okada et al. · Annals of the Rheumatic Diseases · 2016 · 568 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

Peter Nash, Bruce Kirkham, Masato Okada et al. · The Lancet · 2017 · 405 citations · Full text

Medicine, Immunology, Pharmacotherapy +13

Asymptomatic microscopic hematuria in adults: summary of the AUA best practice policy recommendations.

Gary D. Grossfeld, J. Stuart Wolf, Hedvig Hricak et al. · PubMed · 2001 · 187 citations

Medicine, Nephrology, Urology +13

Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)

Désirée van der Heijde, Dafna D. Gladman, Mitsumasa Kishimoto et al. · The Journal of Rheumatology · 2017 · 123 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)

Vinod Chandran, Désirée van der Heijde, Roy Fleischmann et al. · Lara D. Veeken · 2020 · 54 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +12